Evenity (Romosozumab PFS) 105mg x 1.17ml

Evenity (Romosozumab) is a prescription medication in a prefilled syringe, used to strengthen bones in postmenopausal osteoporosis. It helps reduce fracture risk by increasing bone density. This 105mg strength formulation is designed for subcutaneous administration.

Strength

105mg x 1.17ml

Pack Size

Manufacturer / TM Owner

UCB-PHARMA AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Romosozumab is prescribed to treat osteoporosis in postmenopausal women at high risk for fracture. It works by increasing bone formation and reducing bone breakdown. This medication is typically used when other osteoporosis treatments have not been effective or tolerated. It is not intended for general bone health or in patients without osteoporosis.

Side Effects

Romosozumab helps improve bone mineral density by stimulating new bone growth. Patients may notice improved mobility and reduced discomfort associated with osteoporosis over time. The effects are typically observed through bone density scans rather than immediate symptom relief. Regular use is important to maintain benefits.

Precautions & Warnings

Romosozumab should be administered by a healthcare professional in a clinical setting. Patients with a history of heart attack or stroke should discuss risks with their doctor before use. Keep the prefilled syringe refrigerated until use and protect it from light. Do not shake the syringe or use if the liquid is discolored or contains particles.

Avoid Interactions

Romosozumab may interact with medications that affect bone metabolism, such as other osteoporosis treatments. Combining it with certain supplements or therapies could alter its effectiveness. Always inform your healthcare provider about all medications, vitamins, and herbal supplements you are taking. Avoid alcohol and tobacco, as they may impact bone health.

Frequently Asked Questions

Romosozumab is used to treat osteoporosis in postmenopausal women at high risk of fracture.

Evenity is given as an injection under the skin, typically by a healthcare professional.

Romosozumab requires a prescription and is not available for purchase without one.

Common side effects may include joint pain, headache, and injection site reactions.

The safety of long-term use should be discussed with a healthcare provider based on individual health needs.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.